Business risk concept

Barron’s writes:

Johnson & Johnson’s Covid-19 vaccine offers enormous promise as a pathway out of the worst of the pandemic. Delivered as a single dose, without the extreme storage requirements of the vaccines from Pfizer and Moderna, it could speed up global inoculation if it proves effective.

But on Wednesday, the New York Times reported that the company is facing delays in the manufacturing of the vaccine that have put it up to two months behind its initial production schedule. The report comes amid growing anticipation for data from Johnson ...

Subscription Required

In order to view the entire article please either register an account and subscribe or login with a valid subscription below

Please Register

Please either or click register below to continue Register